2026 Annual Meeting | C75 - Motor Neuron Disease

Date Sunday 04/19/26

Time 03:30 PM - 05:30 PM CDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Colin Quinn, MD

Topic(s) Epilepsy/Clinical Neurophysiology (EEG)

Learning Objectives Participants should become familiar with ALS diagnosis, underlying pathophysiology, and current treatment options, and become familiar with Spinobulbar Muscular Atrophy (SBMA) diagnosis, pathophysiology, and potential treatment approaches.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Introductory

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Event Timeline
03:30 PM - 04:05 PM CDT	Speaker	ALS Diagnosis and Treatment: Current Options and Promising Opportunities Colin Quinn, MD
04:05 PM - 04:40 PM CDT	Speaker	What Causes ALS? Review and Update on ALS Pathophysiology Defne Amado, MD, PhD
04:40 PM - 05:15 PM CDT	Speaker	Spinobulbar Muscular Atrophy: Review and Update Christopher Grunseich, MD
05:15 PM - 05:30 PM CDT	Speaker	Questions and Answers Colin Quinn, MD, Defne Amado, MD, PhD, Christopher Grunseich, MD

Faculty Disclosures
Colin Quinn, MD	Dr. Quinn has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abcuro. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Voyager Therapeutics. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Catalyst Pharmaceuticals.
Defne Amado, MD, PhD	Dr. Amado has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Leal Therapeutics. Dr. Amado has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx/Vyvgart. Dr. Amado has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Molecular Therapy. Dr. Amado has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Saltz Mongeluzzi & Bendesky P.C.. The institution of Dr. Amado has received research support from NIH/NINDS. The institution of Dr. Amado has received research support from Active Against ALS. The institution of Dr. Amado has received research support from ASGCT. Dr. Amado has received intellectual property interests from a discovery or technology relating to health care.
Christopher Grunseich, MD	The institution of Dr. Grunseich has received research support from AnnJi Pharmaceuticals.

��ɫ��

��ɫ��